HCW Biologics CFO buys shares and warrants
HCW Biologics Inc. Chief Financial Officer Rebecca Byam bought additional equity in the company on May 22, 2026.
Rhea-AI Filing Summary
HCW Biologics Inc. Chief Financial Officer Rebecca Byam bought additional equity in the company on May 22, 2026. She purchased 14,235 shares of common stock at an average price of $1.405 per share, increasing her direct common stock holdings to 57,245 shares.
Byam also acquired a Common Stock Purchase Warrant for 14,235 underlying shares with a conversion price of $1.28 per share, expiring on November 22, 2031, bringing her directly held warrants to 18,466. According to the filing, these securities were purchased directly from the issuer in a private placement exempt from Section 16(b) under Rule 16b-3(d).
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 28,470 shares
Net Buy
2 txns
Insider
Byam Rebecca
Role
Chief Financial Officer
Bought
28,470 shs ($20K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock Purchase Warrant | 14,235 | $0.00 | $0.00 |
| Purchase | Common Stock | 14,235 | $1.405 | $20K |
Holdings After Transaction:
Common Stock Purchase Warrant — 18,466 contracts (Direct);
Common Stock — 57,245 shares (Direct)
Footnotes (1)
- F1. The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.
Key Figures
Common shares purchased: 14,235 shares
Purchase price per share: $1.405/share
Common shares held after: 57,245 shares
+5 more
8 metrics
Common shares purchased
14,235 shares
Open-market coded purchase on May 22, 2026
Purchase price per share
<money>$1.405</money>/share
Common stock bought by CFO Rebecca Byam
Common shares held after
57,245 shares
Direct common stock holding post-transaction
Warrant underlying shares
14,235 shares
Common Stock Purchase Warrant acquired May 22, 2026
Warrant exercise price
<money>$1.28</money>/share
Conversion price for warrant underlying common stock
Warrants held after
18,466 underlying shares
Total underlying shares from warrants after transaction
Warrant expiration
<date>November 22, 2031</date>
Expiry date of Common Stock Purchase Warrant
Net shares bought
28,470 shares
Net buy direction across common and derivative
Key Terms
Common Stock Purchase Warrant, private placement, Section 16(b), Rule 16b-3(d)
4 terms
Common Stock Purchase Warrant financial
"Common Stock Purchase Warrant for 14,235 underlying shares with a conversion price"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
private placement financial
"purchased these shares directly from the issuer in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Section 16(b) regulatory
"purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HCW Biologics (HCWB) CFO Rebecca Byam buy in this Form 4?
The CFO bought 14,235 shares of common stock and a Common Stock Purchase Warrant for 14,235 underlying shares. Both were acquired directly from HCW Biologics in a private placement exempt under Rule 16b-3(d).
What are the key terms of the HCWB warrant bought by the CFO?
The Common Stock Purchase Warrant covers 14,235 underlying common shares at a conversion price of $1.28 per share. It became exercisable on May 22, 2026 and expires on November 22, 2031, based on the disclosed derivative transaction details.
Was the HCW Biologics (HCWB) CFO’s purchase an open-market trade?
Although coded as a purchase, the footnote explains the CFO bought the securities directly from HCW Biologics in a private placement. The transaction is exempt from Section 16(b) under Rule 16b-3(d) of the Securities Exchange Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
